Teikoku Seiyaku Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Higashikagawa Japan (1848)
Status: No NME R&D (1848)

Organization Overview

First Clinical Trial
2016
NCT02729207
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Teikoku Sayaku Co. Ltd. | Teikoku Seiyaku Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

esflurbiprofen (2 trials)

tt-063 (1 trial)

Drugs in Phase 1 Trials (1)

flurbiprofen (ansaid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Ankle Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3